3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Leukemia, Myeloid, Acute
7
Recurrence
5
Colonic Neoplasms
5
Thyroid Neoplasms
4
Thyroid Diseases
4
Thyroid Cancer, Papillary
4
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Neuroblastoma
4
Neoplasms by Site
4
Lung Neoplasms
4
Lung Diseases
4
Head and Neck Neoplasms
4
Endocrine System Diseases
4
Endocrine Gland Neoplasms
4
Carcinoma, Bronchogenic
4
Bronchial Neoplasms
4
Breast Neoplasms
4
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Central Nervous System Neoplasms
3
Carcinoma, Medullary
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Interventions
pembrolizumab
1
enfortumab vedotin
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Has announcements
×
Carcinoma, Transitional Cell
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA